Charlestown, MA, United States of America

James Lawrence Stanton

USPTO Granted Patents = 1 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2007

Loading Chart...
1 patent (USPTO):Explore Patents

Title: James Lawrence Stanton: Innovator in Pharmacological Compounds

Introduction: James Lawrence Stanton, based in Charlestown, MA, is a distinguished inventor with a notable contribution to the field of pharmacology. He holds a patent for heterocyclic compounds that offer potential therapeutic applications in tackling various health conditions.

Latest Patents: Stanton's patent, titled "Heterocyclic compounds and methods of use," encompasses a range of chemical compounds that serve as pharmacological agents. These compounds act as potent agonists of Peroxisome Proliferator-Activated Receptors (PPARs), making them useful in treating conditions such as dyslipidemia, hyperlipidemia, and several cardiovascular diseases. The patent highlights the efficacy of these compounds specifically for managing conditions related to glucose tolerance and insulin resistance, including type-1 and type-2 diabetes.

Career Highlights: Stanton is affiliated with Novartis AG, a global healthcare company renowned for its innovative medicines. His work focuses on developing novel therapies aimed at improving health outcomes for patients suffering from a wide array of diseases.

Collaborations: Throughout his career, Stanton has collaborated with talented individuals in his field, including Andrew Thomas Bach and Prasad Koteswara Kapa. These partnerships underscore the importance of teamwork in driving innovation in pharmaceutical research and development.

Conclusion: James Lawrence Stanton exemplifies the spirit of innovation in pharmacology. Through his groundbreaking patent on heterocyclic compounds, he contributes significantly to the advancement of medicine aimed at addressing critical health issues. His work not only reflects personal achievement but also represents the collaborative efforts within the pharmaceutical industry to improve patient care and health outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…